On April 3, 2025, Zhu Xihong, Chairman of Suzhou High-tech Zone CPPCC, Bao Donghui, Vice Chairman of Suzhou High-tech Zone CPPCC, Shao Liang, Secretary General of Suzhou High-tech Zone CPPCC, Zhang Jinhong, Director of Suzhou High-tech Zone CPPCC Office, Wu Wenquan, Director of Suzhou High-tech Zone CPPCC Hong Kong, Macao, Taiwan and Overseas Chinese Affairs Committee, Chen Yingjia, Deputy Director of Suzhou High-tech Zone United Front Work Department, and Li Ming, Director of Suzhou High-tech Zone United Front Work Liaison Service Center, visited Suzhou Chung-Hwa Chemical & Pharmaceutical (hereinafter referred to as the Company) for investigation and research. Wang Houjie, Vice President of the Company, and others accompanied them and participated in the discussion.

Innovation Driven

As a pharmaceutical company invested by Taiwan Sinochem Holdings in the mainland, the company has always focused on the field of medicine and health since its establishment in 1993, gradually transforming from mainly producing antibiotics to mainly producing drugs for geriatric diseases and chronic diseases, covering a comprehensive pharmaceutical company of psychotropic drugs and health products. The delegation visited the company's exhibition hall and watched promotional videos to gain an in-depth understanding of its development history, R&D system, intelligent production line and market development strategy.

Cohesion Development

At the symposium, the delegation focused on the company's response strategies under the background of normalization of national drug centralized procurement. Vice President Wang Houjie introduced that the company, through the dual-wheel drive of "fine management + differentiated layout", on the one hand optimizes the market layout, on the other hand accelerates the expansion into chronic disease management, psychiatric drugs and health, and gradually forms a diversified product matrix.

The delegation highly praised the company's strategy of proactively seeking change. The transformation and upgrading of Suzhou Chung-Hwa Chemical & Pharmaceutical provides a model for Taiwanese companies to cope with the new pharmaceutical policies in mainland China.

Drawing a blueprint together

The delegation particularly emphasized that Suzhou Chung-Hwa Chemical & Pharmaceutical, as an outstanding representative of Taiwanese enterprises, has made positive contributions to promoting cross-strait economic and cultural exchanges. At the meeting, representatives of the CPPCC extended an invitation to Vice President Wang Houjie, hoping that he would join the "Consultation and Deliberation Alliance" to gather more wisdom from Taiwanese businessmen and young people and promote the implementation of policies that benefit Taiwan.

Vice President Wang Houjie responded: "The mainland market provides a broad stage for Taiwanese companies. We will continue to play a bridging role, assist Taiwanese compatriots to integrate into the local development ecology, and work together to explore new opportunities in the big health industry."